| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Renal Physiology Laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar-Saba, Israel
2 Renal Physiology Laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar-Saba, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
* To whom correspondence should be addressed. E-mail: nephrol{at}clalit.org.il.
Parathyroid hormone (PTH), the major systemic calcium-regulating hormone has been linked to uremic vascular changes. Considering the possible deleterious action of PTH on vascular structures, it seemed logical to evaluate the impact of PTH on the receptor of advanced glycation end products (RAGE) and interleukin 6 (IL-6) mRNA and protein expression, taking into account that such parameters might be involved in the pathogenesis of vascular calcification, atherosclerosis and/or arteriolosclerosis. Human umbilical vein cords endothelial cells (HUVEC) were stimulated for 24 hours with 10-12-10-10 mol/L PTH. The mRNA expression of RAGE and IL-6 was established by reverse transcriptase/PCR techniques. RAGE protein levels were determined by western blot and IL-6 secretion was measured by ELISA. The pathways by which PTH may have an effect on HUVEC functions were evaluated. PTH (10-11-10-10mol/L) significantly increased RAGE mRNA and protein expression .PTH also significantly increased IL-6 mRNA expression without no changes at protein levels. The addition of protein kinase (PKC or PKA) inhibitors or Nitric oxide (NO) synthase inhibitors significantly reduced the RAGE and IL-6 mRNA expression and the RAGE protein expression. PTH stimulates the mRNA expressions of RAGE and IL-6 and the protein expression of RAGE. These stimulatory effects are probably through PKC and PKA pathways and are also NO dependent. Such data may explain the possible impact of PTH on the atherosclerotic and arteriosclerotic progression.
This article has been cited by other articles:
|
|
 |
|
  Y. Talmor-Barkan, G. Rashid, I. Weintal, J. Green, J. Bernheim, and S. Benchetrit Low extracellular Ca2+: a mediator of endothelial inflammation Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3306 - 3312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hagstrom, P. Hellman, T. E. Larsson, E. Ingelsson, L. Berglund, J. Sundstrom, H. Melhus, C. Held, L. Lind, K. Michaelsson, et al. Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community Circulation, June 2, 2009; 119(21): 2765 - 2771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Vervloet and J. W. R. Twisk Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data Nephrol. Dial. Transplant., March 1, 2009; 24(3): 703 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rashid, E. Plotkin, O. Klein, J. Green, J. Bernheim, and S. Benchetrit Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C Am J Physiol Renal Physiol, January 1, 2009; 296(1): F60 - F66. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
